Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 25 tags : Disease save search
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
Published: 2021-10-25 (Crawled : 00:00) - biospace.com/
FDMT | News | $24.71 -2.33% -2.39% 420K
|
Health Technology
|
| O: 0.22%
H: 2.43%
C: 1.48%
disease phase 1 results molecular trial phase 2 phase 3
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
ACAD | $17.08 -0.64% -0.64% 990K
|
Health Technology
|
| O: -0.49%
H: 0.6%
C: -5.91%
disease alzheimer dementia clinical trials parkinson trials trial conference alzheimer’s alzheimer's disease alzheimer's
Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
Published: 2021-10-25 (Crawled : 13:15) - biospace.com/
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: 0.0%
H: 3.9%
C: 2.39%
disease
New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis
Published: 2021-10-25 (Crawled : 12:15) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.32%
H: 0.36%
C: 0.22%
disease therapy results ulcerative colitis
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
Published: 2021-10-25 (Crawled : 12:00) - prnewswire.com
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.28%
H: 1.95%
C: 0.9%
disease liver disease liver
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: -0.69%
H: 1.61%
C: 0.11%
disease media treatment phase 1 phase 2 clearance
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Published: 2021-10-25 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.89%
H: 0.26%
C: -0.12%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.38%
H: 0.88%
C: 0.44%
disease phase 3 trial dupixent
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.